<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Drosophila melanogaster multisubstrate <z:chebi fb="0" ids="23636">deoxyribonucleoside</z:chebi> kinase (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">Dm</z:e>-dNK) was applied as a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> gene therapeutic approach </plain></SENT>
<SENT sid="1" pm="."><plain>To improve the antitumor effect of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">Dm</z:e>-dNK, a novel <z:e sem="disease" ids="C0812393,C0038661" disease_type="Mental or Behavioral Dysfunction;Injury or Poisoning" abbrv="">suicide</z:e> gene system based on an oncolytic adenovirus vector was developed to produce therapeutic effects towards <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>We constructed an oncolytic adenoviral vector (ZD55), which was designed by deletion of the E1B-55 kDa gene for selective replication in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, containing <z:e sem="disease" ids="C0812393,C0038661" disease_type="Mental or Behavioral Dysfunction;Injury or Poisoning" abbrv="">suicide</z:e> gene (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">Dm</z:e>-dNK) driven by a cytomegalovirus promoter </plain></SENT>
<SENT sid="3" pm="."><plain>We analysed the expression and activity of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">Dm</z:e>-dNK in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells (HCT-116 and SW620) via reverse transcription (RT)-PCR and enzyme assay </plain></SENT>
<SENT sid="4" pm="."><plain>We assessed selective cytotoxic effects of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">Dm</z:e>-dNK with the presence of the analogs (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), difluorodeoxycytidine (dFdC) or 1-Î²-D-arabinofuranosylthymine (ara-T) by <z:chebi fb="0" ids="53233">MTT</z:chebi> and FACS; the variation of oncolytic adenovirus was detected by titer assay and western blot analysis </plain></SENT>
<SENT sid="5" pm="."><plain>Our data showed that ZD55-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">Dm</z:e>-dNK mediated high expression of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">Dm</z:e>-dNK in HCT-116 and SW620 <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines and low levels of expression in WI-38 and MRC-5 <z:mpath ids='MPATH_458'>normal</z:mpath> cells, strong cytotoxicity was observed only in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells after ZD55-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">Dm</z:e>-dNK <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> combined with <z:chebi fb="0" ids="33838">nucleoside</z:chebi> analogs (NA) </plain></SENT>
<SENT sid="6" pm="."><plain>When ZD55-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">Dm</z:e>-dNK was combined with BVDU or dFdC, it produced a synergistic inhibitive effect of adenovirus replication while maintaining specific <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell killing activity </plain></SENT>
<SENT sid="7" pm="."><plain>The results suggest that the novel oncolytic virus ZD55-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">Dm</z:e>-dNK, in combination with NA, has potential as an efficient selective antitumoral agent and may produce synergistic effects in safe control of adenovirus, which is a new promising therapeutic for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>